Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

Inclusion Criteria: * 25 years or older. * Huntington's Disease confirmed through genetic testing, with a specific change in exon 1 of the HTT gene (CAG repeat of 40 or more). * Total Functional Capacity (TFC) score of 10 or more). * Total Motor Score (TMS) of 6 or more). * Independence Score (IS) of 70 or more). * Women who can have children must have a negative pregnancy test before starting and use two types of birth control during the study and for 30 days after the last dose of the study drug. * Men must agree to use birth control during the study and for 90 days after the last dose. * Agree to sign a consent form and follow the study's rules and schedule. Exclusion Criteria: * Other Serious health problems or brain/spinal issues that could interfere with the study or make procedures unsafe. * Conditions that interfere with protocol-specified assessments, like an implanted medical device or difficulty getting an MRI. * Cancer, except for some types of skin cancer, or a history of cancer in the last five years. * Severe allergies or have reacted badly to similar drugs in the past. * Taking medications or treatments that might interfere with the study. * Participated in another study or taken experimental drugs in the last two months (or longer for some drugs). * Any kind of gene therapy. * History of suicidal thoughts, severe depression, or have attempted suicide in the past year. * Liver function tests show significant abnormalities. * Positive for hepatitis B, hepatitis C, or HIV. * Pregnancy, breastfeeding, or planning to become pregnant during the study.